Solventum Corporation $SOLV Shares Sold by Vanguard Personalized Indexing Management LLC

Vanguard Personalized Indexing Management LLC decreased its holdings in Solventum Corporation (NYSE:SOLV) by 9.6% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,061 shares of the company’s stock after selling 1,608 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Solventum were worth $1,176,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Independent Franchise Partners LLP grew its holdings in Solventum by 263.1% in the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after purchasing an additional 4,217,570 shares during the period. Boston Partners increased its holdings in Solventum by 101.3% in the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock worth $255,554,000 after acquiring an additional 1,691,565 shares in the last quarter. Nuveen LLC acquired a new position in Solventum during the first quarter worth $35,375,000. Diamond Hill Capital Management Inc. lifted its holdings in Solventum by 139.6% during the first quarter. Diamond Hill Capital Management Inc. now owns 577,173 shares of the company’s stock valued at $43,888,000 after purchasing an additional 336,282 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new position in Solventum during the first quarter valued at $23,572,000.

Solventum Stock Performance

Shares of Solventum stock opened at $72.11 on Friday. The business’s 50 day moving average price is $72.63 and its 200 day moving average price is $71.95. The company has a market cap of $12.50 billion, a price-to-earnings ratio of 33.38, a PEG ratio of 2.94 and a beta of 0.50. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. Solventum Corporation has a one year low of $60.70 and a one year high of $85.92.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.45 by $0.24. Solventum had a return on equity of 29.93% and a net margin of 4.52%.The business had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. During the same period last year, the company earned $1.56 EPS. The company’s revenue for the quarter was up 3.8% on a year-over-year basis. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Upgrades and Downgrades

SOLV has been the subject of a number of research reports. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th. Argus upgraded Solventum from a “hold” rating to a “buy” rating and set a $90.00 price objective on the stock in a report on Tuesday, July 1st. Weiss Ratings reissued a “hold (c-)” rating on shares of Solventum in a report on Wednesday, October 8th. Jefferies Financial Group initiated coverage on Solventum in a research note on Thursday, September 11th. They issued a “hold” rating and a $80.00 price target on the stock. Finally, Zacks Research upgraded Solventum from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 15th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $84.89.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.